Verve Therapeutics Inc (NASDAQ:VERV) shares, rose in value, with the stock price down by -0.34% to the previous day’s close as strong demand from buyers drove the stock to $8.68.
Actively observing the price movement in the last trading, the stock closed the session at $8.71. The value of beta (5-year monthly) was 1.77. Referring to stock’s 52-week performance, its high was $21.42, and the low was $7.36. On the whole, VERV has fluctuated by -42.67% over the past month.
As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.73, which is expected to increase to -$0.6 for fiscal year -$2.98 and then to about -$3.22 by fiscal year 2025. Data indicates that the EPS growth is expected to be 4.50% in 2025, while the next year’s EPS growth is forecast to be -8.10%.
According to the average forecast, sales growth in current quarter could jump up 80.20%, compared to the corresponding quarter of last year. Wall Street analysts also predicted that in 2025, the company’s y-o-y revenues would reach $14.46 million, representing an increase of 23.00% from the revenues reported in the last year’s results.
Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that VERV’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of Hold while long term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of VERV currently trading nearly -34.04% and -33.83% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 26.08, while the 7-day volatility ratio is showing 10.60% which for the 30-day chart, stands at 7.15%. Furthermore, Verve Therapeutics Inc (VERV)’s beta value is 1.75, and its average true range (ATR) is 1.13.
A comparison of Verve Therapeutics Inc (VERV) with its peers suggests the former has fared considerably weaker in the market. VERV showed an intraday change of -0.34% in last session, and over the past year, it shrunk by -39.76%%.
Data on historical trading for Verve Therapeutics Inc (NASDAQ:VERV) indicates that the trading volumes over the past 10 days have averaged 1.84 million and over the past 3 months, they’ve averaged 1.25 million. According to company’s latest data on outstanding shares, there are 81.97 million shares outstanding.
Nearly 30.25% of Verve Therapeutics Inc’s shares belong to company insiders and institutional investors own 70.27% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 14.1 million shares as on Mar 15, 2024, resulting in a short ratio of 10.76. According to the data, the short interest in Verve Therapeutics Inc (VERV) stood at 16.87% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 12.59 million. The stock has fallen by -37.73% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the VERV stock heading into the next quarter.
